Global Asthma Market 2014-2018

世界の喘息治療市場:気管支拡張薬、ロイコトリエン拮抗薬、肥満細胞安定化薬、免疫抑制剤

◆タイトル:Global Asthma Market 2014-2018
◆商品コード:IRTNTR4048
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年9月3日
◆ページ数:91
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥316,400見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"世界の喘息治療市場:気管支拡張薬、ロイコトリエン拮抗薬、肥満細胞安定化薬、免疫抑制剤"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Asthma and its Categories
Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.

TechNavio’s analysts forecast the Global Asthma Market to grow at a CAGR of 4.50 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Asthma market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various class of drugs used in the treatment of asthma:
• Bronchodilators
• Leukotriene antagonists
• Mast cell stabilizers
• Immunosuppressants

TechNavio’s report, the Global Asthma Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Asthma Market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Merck
• Novartis

Other Prominent Vendors
• Abbott
• Actavis
• Amgen
• AptarGroup
• Astellas
• Aurobindo
• Biotest
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• Cytos
• Dainippon Sumitomo
• Dr. Reddy’s Laboratories
• Glenmark
• Medicinova
• Mylan
• Ono Pharmaceutical
• Orchid Chemicals and Pharmaceuticals
• Perrigo
• Pfizer
• Ranbaxy
• Rottapharm Madaus
• Skyepharma
• Sosei
• Sunovion
• Teva
• Theravance
• Vectura

Market Driver
• Rise in Prevalence of Disease
• For a full, detailed list, view our report

Market Challenge
• Unknown Etiology of Disease
• For a full, detailed list, view our report

Market Trend
• Popularity of Combination Therapies
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Class of Drugs
07.1 Bronchodilators
07.2 Leukotriene Antagonists
07.3 Mast Cell Stabilizers
07.4 Immunosuppressants
07.5 Combination of LABA/ICS
08. Global Bronchodilators Market
08.1 Market Overview
08.2 Market Size and Forecast
09. Global Leukotriene Antagonists Market
09.1 Market Overview
09.2 Market Size and Forecast
10. Global Mast Cell Stabilizers Market
10.1 Market Overview
10.2 Market Size and Forecast
11. Global Immunosuppressants Market
11.1 Market Overview
11.2 Market Size and Forecast
12. Global Combination of ICS/LABA Market
12.1 Market Overview
12.2 Market Size and Forecast
13. Global Other Asthma Drugs Market
13.1 Market Overview
13.2 Market Size and Forecast
14. Geographical Segmentation
14.1 Global Asthma Market by Geographical Segmentation 2013-2018
14.2 Asthma Market in the US
14.2.1 Market Overview
14.2.2 Market Size and Forecast
14.3 Asthma Market in the Russia
14.3.1 Market Overview
14.3.2 Market Size and Forecast
14.4 Asthma Market in the India
14.4.1 Market Overview
14.4.2 Market Size and Forecast
15. Rate of Incidence and Prevalence
16. Buying Criteria
17. Market Growth Drivers
18. Drivers and their Impact
19. Market Challenges
20. Impact of Drivers and Challenges
21. Market Trends
22. Trends and their Impact
23. Vendor Landscape
23.1 Competitive Scenario
23.1.1 Key News
23.1.2 Mergers and Acquisitions
23.2 Market Share Analysis 2013
23.2.1 AstraZeneca
23.2.2 GlaxoSmithKline
23.2.3 Merck
23.2.4 Novartis
23.2.5 Roche
23.3 Other and Future Prominent Vendors
24. Pipeline Portfolio
25. Key Vendor Analysis
25.1 AstraZeneca plc
25.1.1 Key Facts
25.1.2 Business Description
25.1.3 Business Segmentation
25.1.4 Business Strategy
25.1.5 Revenue by Business Segmentation
25.1.6 Revenue Comparison 2011-2013
25.1.7 Sales Revenue by Geographical Segmentation
25.1.8 Key Developments
25.1.9 SWOT Analysis
25.2 Hoffmann La Roche
25.2.1 Key Facts
25.2.2 Business Overview
25.2.3 Business Segmentation by Revenue 2013
25.2.4 Business Segmentation by Revenue 2012 and 2013
25.2.5 Geographical Segmentation by Revenue 2013
25.2.6 Business Strategy
25.2.7 Recent Developments
25.2.8 SWOT Analysis
25.3 GlaxoSmithKline
25.3.1 Key Facts
25.3.2 Business Overview
25.3.3 Business Segmentation
25.3.4 Business Segmentation by Revenue 2012 and 2013
25.3.5 Sales by Geography
25.3.6 Pipeline Products
25.3.7 Business Strategy
25.3.8 Key Information
25.3.9 SWOT Analysis
25.4 Merck
25.4.1 Key Facts
25.4.2 Business Overview
25.4.3 Business Segmentation by Revenue 2013
25.4.4 Business Segmentation by Revenue 2012 and 2013
25.4.5 Sales by Geography
25.4.6 Business Strategy
25.4.7 Key Developments
25.4.8 SWOT Analysis
25.5 Novartis
25.5.1 Key Facts
25.5.2 Business Overview
25.5.3 Business Segmentation by Revenue 2013
25.5.4 Business Segmentation by Revenue 2012 and 2013
25.5.5 Sales by Geography
25.5.6 Business Strategy
25.5.7 Key Developments
25.5.8 SWOT Analysis
26. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Asthma Market 2014-2018 (US$ million)
Exhibit 3: Global Asthma Market Segmentation by Class of Drugs
Exhibit 4: Global Asthma Market Segmentation by Class of Drugs 2013
Exhibit 5: Global Bronchodilators Market 2013-2018 (US$ million)
Exhibit 6: Global Leukotriene Antagonists Market 2013-2018 (US$ million)
Exhibit 7: Global Mast Cell Stabilizers Market 2013-2018 (US$ million)
Exhibit 8: Global Immunosuppressants Market 2013-2018 (US$ million)
Exhibit 9: Global Combination of ICS/LABA Market 2013-2018 (US$ million)
Exhibit 10: Global Other Asthma Drugs Market 2013-2018 (US$ million)
Exhibit 11: Global Asthma Market by Geographical Segmentation 2013
Exhibit 12: Asthma Market in the US 2013-2018 (US$ million)
Exhibit 13: Asthma Market in Russia 2013-2018(US$ million)
Exhibit 14: Asthma Market in India 2013-2018 (US$ million)
Exhibit 15: Prescription Trend Chart of the Popular Asthma Drugs in the US 2013
Exhibit 16: Global Asthma Market Share Analysis 2013
Exhibit 17: Global Sales of Symbicort 2009-2012 (in US$ million)
Exhibit 18: Geography-wise Sales of Symbicort 2009-2012 (US$ million)
Exhibit 19: Global Sales of Pulmicort 2009-2012 (US$ million)
Exhibit 20: Geography-wise Sales of Pulmicort 2009-2012 (US$ million)
Exhibit 21: Global Sales of Singulair 2011-2013 (US$ million)
Exhibit 22: Global Sales of Dulera 2011-2013 (US$ million)
Exhibit 23: Global Sales Forecast of Dulera 2013-2016 (US$ million)
Exhibit 24: Pipeline Snapshot of Asthma Drugs
Exhibit 25: Sales Forecast of QMF-149 2016-2018 (US$ million)
Exhibit 26: AstraZeneca plc: Business Segmentation
Exhibit 27: AstraZeneca plc: Revenue by Business Segmentation2013
Exhibit 28: AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 29: AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
Exhibit 30: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 31: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 32: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
Exhibit 33: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
Exhibit 34: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 35: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 36: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 37: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 38: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 39: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 40: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 41: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 42: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 43: Novartis AG: Sales by Geography 2013



【掲載企業】

AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis , Abbott, Actavis, Amgen, AptarGroup, Astellas, Aurobindo, Biotest, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, Cytos, Dainippon Sumitomo, Dr. Reddy's Laboratories, Glenmark, Medicinova, Mylan, Ono Pharmaceutical, Orchid Chemicals and Pharmaceuticals, Perrigo, Pfizer, Ranbaxy, Rottapharm Madaus, Skyepharma, Sosei, Sunovion, Teva, Theravance, Vectura

【資料のキーワード】

喘息治療、ぜんそく、製薬、気管支拡張薬、ロイコトリエン拮抗薬、肥満細胞安定化薬、免疫抑制剤

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[世界の喘息治療市場:気管支拡張薬、ロイコトリエン拮抗薬、肥満細胞安定化薬、免疫抑制剤] (Global Asthma Market 2014-2018 / IRTNTR4048)販売に関する免責事項
[世界の喘息治療市場:気管支拡張薬、ロイコトリエン拮抗薬、肥満細胞安定化薬、免疫抑制剤] (Global Asthma Market 2014-2018 / IRTNTR4048)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆